BIMZELX® (bimekizumab-bkzx) Reference Document- Psoriatic Arthritis

BIMZELX® is indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. See Full Prescribing Information for additional details.

This document contains information on the use of bimekizumab in disease states where the safety and efficacy have not been established. BIMZELX® is not currently approved for the treatment of psoriatic arthritis.

Psoriatic Arthritis Manuscripts

BE OPTIMAL (16 WK)

McInnes I, Asahina A, Coates L, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo controlled, phase 3 trial. *Lancet* 2023; 401: 25-37.

Synopsis: Primary outcome measure was ACR50 response at week 16. Additional analyses presented include ACR20, ACR70, PASI, MDA and safety. Data presented to week 24.

BE OPTIMAL (52 WK)

Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomized, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis 2023; 82: 1404-1414.

Synopsis: Safety and efficacy analyses presented to week 52. Efficacy analyses presented include ACR50, ACR20, ACR70, PASI and MDA.

BE COMPLETE (16WK)

Merola J, Landewe R, McInnes I, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 38-48.

Synopsis: Primary outcome measure was ACR50 response at week 16. Additional analyses presented include ACR20, ACR70, PASI, MDA and safety.

BE COMPLETE + OLE (52 WK)

Coates LC, Landewé R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open 2024; 10:e003855.

Synopsis: Safety profile to week 52 presented. Efficacy analyses including ACR, PASI and MDA presented to week 52.